Lagos Pharma Conference Tells Sales Reps: Patients Before Profit

Nigeria's pharmaceutical sales profession got a new job description at the 2026 National Pharmaceutical Sales and Marketing Conference in Lagos. Speakers told attendees to put patient safety above profit, or risk watching public trust and drug quality collapse together.

The Society for Pharmaceutical Sales and Marketing of Nigeria (SPSMN) hosted the event under the theme "From Sales Rep to Trusted Transformation Leader: Raising Professional Standards and Capacity in Pharma." Senior executives, clinical educators and technology experts attended. The backdrop is unglamorous: counterfeit and substandard medicines are spreading, operational costs are rising, and public confidence in the industry is thin.

What did the keynote actually ask for?

Sola Solarin, Managing Partner of Savante Consulting Limited and former National Chairman of the Association of Industrial Pharmacists of Nigeria, delivered the keynote. He argued that sales representatives must stop acting as product dealers. Their real mandate, he said, is clinical education and strategic support for health systems.

That claim came with a concrete metric shift. Solarin proposed evaluating performance not solely by sales volume but by three additional measures:

• the number of healthcare providers trained,
• pharmacovigilance reports facilitated,
• patient education programmes supported.

No baseline figures for these metrics were offered at the event, so the shift remains a proposal rather than a measured outcome. It is a stated direction, not yet a scoreboard.

How do executives want AI used?

Ope Oyinola, Managing Director and CEO of Charterhouse Pharmaceutical Limited, framed sales and marketing professionals as strategic partners rather than mere distributors. He argued that placing patient safety at the core of all activity would inherently drive quality, sales and profitability — an assertion, though a testable one if the new metrics take hold.

Oyinola backed adoption of artificial intelligence and other digital tools for medication traceability, inventory management and quality verification. He drew one boundary clearly. "Let us use AI not as an answer, but as a tool for efficiency and safety," he said.

The distinction matters. Efficiency tooling is a modest claim; autonomous decision-making in promotion would be a different conversation entirely.

What did the SPSMN president warn against?

SPSMN President Tunde Oyeniran warned members against unethical practices, exaggerated claims and misinformation. He said such conduct erodes confidence in individual drugs and in the industry as a whole.

His prescription was plain: know your products and markets, and communicate honestly and accurately. Oyeniran noted the society was founded to give pharmaceutical sales and marketing professionals in Nigeria identity, dignity and direction. That benchmark for professional conduct, he said, must now evolve to meet contemporary challenges.

Is this a real shift or a slogan?

The conference material describes a paradigm shift uniting scientific rigour, patient welfare and technological innovation. Attendees reportedly left committed to professional standards, continuous learning and digital tools for safer pharmaceutical marketing ecosystems.

What is measured here is attendance and rhetoric. What is asserted is transformation. The gap between the two will close only when the new performance metrics — trained providers, pharmacovigilance reports, patient programmes — start appearing in actual evaluations.

If SPSMN members adopt Solarin's metric framework, 2026 could mark the year Nigerian pharma sales stopped counting boxes and started counting outcomes.